Till startsida
To content Read more about how we use cookies on gu.se

Astra Zenecas view on the Wallenberg Centre

With the emphasis on translational and crossfunctionl research, scientists from the Wallenberg Centre for Molecular and Translational Medicine (WCMTM), Gothenburg University and AstraZeneca shared their achievements and scientific outlooks for new ways to collaborate across and build on the Gothenburg ecosystem of science.

”The science we support here is quite fundamental to how AstraZeneca has changed. We want to be open, collaborative and sharing with what we know, to learn more. This centre is a great addition to the Gothenburg life-science ecosystem and the strategic long-term investment in up-and-coming competitive scientists is right for the future.” said Marcus Schindler, VP, CVMD, IMED Biotech Unit.

Jeremie Boucher. Photo: Johan Wingborg/GU 

The newly formed WCMTM hosted an inspiring afternoon where selected group leaders presented their science. Primary Investigators Anders Rosengren, Emma Börgeson, Karolina Skibicka and Jeremie Boucher shared their current and future research plans in their individual areas of expertise; the underlying reasons for type two diabetes, lipoxins as promotors for cardiometabolic health in obesity, gut-brain hormones control of ingestive behavior and food reward, and browning mechanism for white adipocytes for the treatment of type 2 diabetes. The day progressed with a presentation of the novel RIA research strategy by Outi Vaarala, Head of Translational Biology, IMED RIA who is also a representative on the WCMTM board. The day ended in a discussion panel, where AstraZeneca was represented by Marcus Schindler, VP IMED CVMD, panellists shared their plans, expectations and advice for the centre going forward. Collaboration, openness, curiosity and the bravery to break new grounds were key hopes for the centre and scientists.

Outi Vaarala. Photo: Johan Wingborg/GU

“It is rewarding to be a representative of AstraZeneca on the board for this initiative, which enables a true and mutual collaboration between industry and academia, and will rapidly enhance our knowledge in translational research. I am looking forward to see more of these bright talents like we have already recruited to WCMTM in Gothenburg.” Outi Vaarala, Head of Translational Biology, IMED RIA, board member of WCMTM

“This is a fantastic opportunity to be a part of this centre and to combine it with my work at AstraZeneca. This centre truly embrace its translational promise where PhD’s, Post Docs, physicians and nurses work side-by-side to create great scientific change” said Jeremie Boucher, Principal Scientist Bioscience Diabetes, CVMD, IMED Biotech Unit.

Academic collaboration, a central part of AstraZeneca

The Wallenberg Centre Molecular and Translational Medicine (WCMTM) is an initiative from Knut and Alice Wallenberg Foundation, to reposition Sweden at the very top of life-science research. Gothenburg University is one of four university hubs where translationally oriented young scientists of outstanding potential will be internationally recruited. The scope of the Centre in Gothenburg is molecular medicine aspects of metabolic and degenerative diseases, neuroscience, inflammation and cancer. Successful candidates will become part of strong research environments with excellent infrastructure and enjoy close collaboration with AstraZeneca and clinical/translational research platforms at one of the largest University hospitals in northern Europe.

“I am proud that AstraZeneca is part of this initiative. We want to be part of building and benefiting the science in Sweden and the Gothenburg region and to be accessible and open to facilitate collaborations.” said Jenny Sundqvist, Site Director

Academic collaboration is a central part of the AstraZeneca strategy to achieve scientific leadership and develop new pharmaceuticals to change the lives of patients. The WCMTM initiative will be a part of intensifying the collaboration between industry, academia and healthcare to make Sweden and the Nordic region an even more attractive life-science cluster. AstraZeneca aim to create joint positions both at senior and junior levels.

Page Manager: Pontus Sundén|Last update: 4/21/2017

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?